JP2023550652A5 - - Google Patents

Info

Publication number
JP2023550652A5
JP2023550652A5 JP2023531555A JP2023531555A JP2023550652A5 JP 2023550652 A5 JP2023550652 A5 JP 2023550652A5 JP 2023531555 A JP2023531555 A JP 2023531555A JP 2023531555 A JP2023531555 A JP 2023531555A JP 2023550652 A5 JP2023550652 A5 JP 2023550652A5
Authority
JP
Japan
Prior art keywords
subject
species
composition
compared
reduce
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023531555A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023550652A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/060878 external-priority patent/WO2022115646A1/en
Publication of JP2023550652A publication Critical patent/JP2023550652A/ja
Publication of JP2023550652A5 publication Critical patent/JP2023550652A5/ja
Pending legal-status Critical Current

Links

JP2023531555A 2020-11-25 2021-11-24 移植片対宿主病を処置するための設計された細菌組成物 Pending JP2023550652A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063118639P 2020-11-25 2020-11-25
US63/118,639 2020-11-25
PCT/US2021/060878 WO2022115646A1 (en) 2020-11-25 2021-11-24 Designed bacterial compositions for treating graft-versus-host-disease

Publications (2)

Publication Number Publication Date
JP2023550652A JP2023550652A (ja) 2023-12-04
JP2023550652A5 true JP2023550652A5 (cg-RX-API-DMAC7.html) 2024-12-03

Family

ID=81756137

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023531555A Pending JP2023550652A (ja) 2020-11-25 2021-11-24 移植片対宿主病を処置するための設計された細菌組成物

Country Status (9)

Country Link
US (1) US20240000859A1 (cg-RX-API-DMAC7.html)
EP (1) EP4250932A4 (cg-RX-API-DMAC7.html)
JP (1) JP2023550652A (cg-RX-API-DMAC7.html)
KR (1) KR20230124601A (cg-RX-API-DMAC7.html)
CN (1) CN116709924A (cg-RX-API-DMAC7.html)
AU (1) AU2021388169A1 (cg-RX-API-DMAC7.html)
CA (1) CA3199153A1 (cg-RX-API-DMAC7.html)
MX (1) MX2023006146A (cg-RX-API-DMAC7.html)
WO (1) WO2022115646A1 (cg-RX-API-DMAC7.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4341382A4 (en) * 2021-05-10 2025-04-30 Microba Ip Pty Ltd COMPOSITIONS AND METHODS FOR TREATING DISEASES
CN114788837B (zh) * 2022-06-07 2023-09-05 青岛东海药业有限公司 一种组合物及其在制备治疗和/或预防化疗引起的恶心呕吐的药物中的应用
EP4687930A2 (en) * 2023-01-30 2026-02-11 Seres Therapeutics, Inc. Use of designed bacterial compositions for infection treatment
GB2627012A (en) * 2023-02-13 2024-08-14 Acad Medisch Ct Predictive biomarker of neonatal E.coli mediated sepsis
AU2024327567A1 (en) * 2023-08-22 2026-01-08 Danisco Usa Inc. Methods and compositions for immune system regulation
CN117907608B (zh) * 2024-03-19 2024-05-24 苏州和锐生物科技有限公司 一种Claudin2蛋白的检测方法及其相关产品和应用
CN119055685A (zh) * 2024-09-13 2024-12-03 南方医科大学南方医院 粪副拟杆菌在制备分离移植物抗白血病效应与移植物抗宿主病药物中的应用
CN118987051A (zh) * 2024-09-13 2024-11-22 南方医科大学南方医院 粪副拟杆菌在制备治疗移植物抗宿主病药物中的应用
CN120700173B (zh) * 2025-09-01 2026-01-02 华中科技大学同济医学院附属协和医院 甲状腺相关眼病的微生物标志物、产品及其应用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2015006491A (es) * 2012-11-23 2015-12-03 Seres Health Inc Composiciones bacterianas sinergicas y metodos de produccion y uso de las mismas.
EP2951283A4 (en) * 2013-02-04 2017-01-25 Seres Therapeutics, Inc. Compositions and methods
MX369877B (es) * 2013-02-04 2019-11-25 Seres Therapeutics Inc Composiciones y metodos.
JP2016519664A (ja) * 2013-03-15 2016-07-07 セレス セラピューティクス インコーポレイテッド ネットワークを基にした微生物組成物及び方法
MX367109B (es) * 2013-11-25 2019-08-05 Seres Therapeutics Inc Composiciones bacterianas sinergicas y sus metodos de produccion y usos.
MA41020A (fr) * 2014-11-25 2017-10-03 Evelo Biosciences Inc Compositions probiotiques et prébiotiques, et leurs procédés d'utilisation pour la modulation du microbiome
US20190247447A1 (en) * 2015-11-24 2019-08-15 Seres Therapeutics, Inc. Designed bacterial compositions
EP3379935A4 (en) * 2015-11-25 2019-08-28 Memorial Sloan-Kettering Cancer Center METHOD AND COMPOSITIONS FOR REDUCING VANCOMYCIN RESISTANT ENTEROKOKKEN
AU2017234120B2 (en) * 2016-03-14 2024-06-20 Holobiome, Inc. Modulation of the gut microbiome to treat mental disorders or diseases of the central nervous system
KR102658297B1 (ko) * 2016-06-14 2024-04-18 베단타 바이오사이언시즈, 인크. 클로스트리디움 디피실레 감염의 치료
KR20200038506A (ko) * 2017-08-07 2020-04-13 핀치 테라퓨틱스, 인코포레이티드 건강한 장 장벽을 유지 및 회복시키기 위한 조성물 및 방법
JP2020530493A (ja) * 2017-08-07 2020-10-22 フィンチ セラピューティクス、インコーポレイテッド. 腸内の抗生物質耐性菌を除菌するための組成物及び方法
BR112020002992A2 (pt) * 2017-08-14 2020-08-18 Seres Therapeutics, Inc. composições e métodos para tratamento de doença colestática
JP2021512638A (ja) * 2018-02-09 2021-05-20 学校法人慶應義塾 Cd8+t細胞の誘導のための組成物および方法

Similar Documents

Publication Publication Date Title
Liu et al. The microbiome in inflammatory bowel diseases: from pathogenesis to therapy
Eeckhaut et al. Butyricicoccus pullicaecorum in inflammatory bowel disease
Liu et al. Lactobacillus casei LH23 modulates the immune response and ameliorates DSS-induced colitis via suppressing JNK/p-38 signal pathways and enhancing histone H3K9 acetylation
Shen et al. Bugging inflammation: role of the gut microbiota
Zhang et al. Lactobacillus rhamnosus GG affects microbiota and suppresses autophagy in the intestines of pigs challenged with Salmonella Infantis
Li et al. Current status of probiotics as supplements in the prevention and treatment of infectious diseases
Al-Fakhrany et al. Helicobacter pylori in the post-antibiotics era: from virulence factors to new drug targets and therapeutic agents
JP5948323B2 (ja) L.ジョンソニイLa1、B.ロングムNCC2705及び免疫障害
Möndel et al. Probiotic E. coli treatment mediates antimicrobial human β-defensin synthesis and fecal excretion in humans
JP2020530493A5 (cg-RX-API-DMAC7.html)
Döring et al. BIIL 284 reduces neutrophil numbers but increases P. aeruginosa bacteremia and inflammation in mouse lungs
Pusceddu et al. Targeting the microbiota, from irritable bowel syndrome to mood disorders: focus on probiotics and prebiotics
Alexandre et al. Probiotics: a new way to fight bacterial pulmonary infections?
Elshaghabee et al. Mitigation of antibiotic resistance using probiotics, prebiotics and synbiotics. A review
Cope et al. Novel microbiome-based therapeutics for chronic rhinosinusitis
WO2012142605A1 (en) Rapid recolonization deployment agent
Le et al. Inflammatory bowel disease therapeutic strategies by modulation of the microbiota: how and when to introduce pre-, pro-, syn-, or postbiotics?
Liu et al. Alleviation of DSS-induced colitis in mice by a new-isolated Lactobacillus acidophilus C4
Mikov et al. Probiotics as a promising treatment for inflammatory bowel disease
Ding et al. Harnessing the human gut microbiota: an emerging frontier in combatting multidrug-resistant bacteria
Rudiansyah et al. The emerging microbiome‐based approaches to IBD therapy: from SCFAs to urolithin A
Shukla et al. Comparative analysis of antigiardial potential of heat inactivated and probiotic protein of probiotic Lactobacillus rhamnosus GG in murine giardiasis
Li et al. Changes of intestinal microbiota and microbiota-based treatments in IBD
Yang et al. Metformin alleviates liver fibrosis in mice by enriching Lactobacillus sp. MF-1 in the gut microbiota
Wang et al. A phage cocktail combined with the enteric probiotic Lactobacillus reuteri ameliorated mouse colitis caused by S. typhimurium